Lobbying Filing Details

Total Spending

$970,000

Activities

6

Lobbyists

3

Gov't Entities

24

Filing Information
Filing UUID:
082b3df5-cb3f-420b-bd6c-985a641ef18e
Type:
Q4 - 4th Quarter - Report
Period:
2019 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 21, 2020 at 2:58 PM
Income:
$0
Expenses:
$970,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Daniel Bachner
Registrant
ABBVIE, INC.

Biopharmaceutical company

Washington, District of Columbia
Client
ABBVIE INC.
District of Columbia, United States of America
Lobbying Activities (6)
Activity 1
Budget/Appropriations

H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs
FY 2020 Omnibus Appropriations Bill - Provisions relating to biopharmaceutical products

Lobbyists (3)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • BINTA BEARD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 2
Copyright/Patent/Trademark

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements
H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
Biopharmaceutical innovation and patent policy issues
S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents
Patent litigation reform issues and issues related to post-grant proceeding at the PTO
Value of intellectual property
Patent protection

Lobbyists (3)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • BINTA BEARD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 3
Health Issues

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D
H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing
H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals
H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing
S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues
340B drug discount program policy issues
Drug cost and pricing policy issues
Transparency policy issues
Patient affordability issues

Lobbyists (3)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • BINTA BEARD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 4
Medicare/Medicaid

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights
S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing
Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
Part D policy issues including non-interference, out of pocket cap and rebates policy issues
S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing
S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D
Medicaid policy issues including rebates policy and average manufacture price (AMP) caps
CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs

Lobbyists (3)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • BINTA BEARD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 5
Taxation/Internal Revenue Code

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018
Draft legislation relating to economic activity in Puerto Rico
International tax issues, including OECD digital taxation work program

Lobbyists (2)
  • STEPHEN SCANGO
  • DANIEL BACHNER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)
Activity 6
Trade (domestic/foreign)

USMCA and related policy issues

Lobbyists (2)
  • STEPHEN SCANGO
  • DANIEL BACHNER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Council of Economic Advisers (CEA)
  • Health & Human Services, Dept of (HHS)

Source: LDA.gov, data retrieved November 10, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.